Core Scientific, Inc. (CORZ)
Valuation Overview•Is Core Scientific, Inc. Overvalued or Undervalued?
Market price has outpaced base-case intrinsic cash flows, pricing in significant future growth optimism.
Fragile underlying quality score of 25/100; weak margins or elevated debt leverage warrant caution.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Highly distressed profile flashing severe fundamental warning signs.
Wall Street is broadly bullish, projecting solid upside alongside robust expected earnings growth. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
CORZ struggles with subpar profitability and pressured margins. This is paired with a moderately leveraged but stable balance sheet.
The company is facing top-line contraction (-20.7% 3Y CAGR) paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (-26.3%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $115.2M | -37.5% | -20.7% | +39.5% | — | |
| EBITDA | -$14.7M | — | +57.5% | — | — | |
| Net Income | -$347.2M | +78.1% | +48.8% | — | — | |
| EPS (Diluted) | $-1.06 | +82.9% | — | — | — | |
| Free Cash Flow | -$139.3M | -765.7% | -4.4% | -77.8% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 16.9% | 20.1% | 21.1% | 19.8% |
| Operating Margin | -26.3% | -24.1% | -74.2% | -57.3% |
| Net Margin | -342.9% | -132.3% | -144.7% | -109.1% |
| FCF Margin | -132.8% | -47.2% | -45.0% | -47.3% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.02 | $-0.10 | -400.0% | ||
| Q1'26 | $-0.27 | $-0.29 | -7.4% | ||
| Q4'25 | $-0.07 | $-0.46 | -558.9% | ||
| Q3'25 | $-0.07 | $-0.04 | +42.9% | ||
| Q2'25 | $-0.12 | $-0.10 | +16.7% | ||
| Q1'25 | $-0.10 | $-0.01 | +90.0% | ||
| Q4'24 | $-0.11 | $-0.13 | -18.2% | ||
| Q3'24 | $-0.05 | $-0.04 | +20.0% |
Total return is +145.0% (1Y), outperforming the benchmark by +120.1%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +82.4% | +73.1% | — |
| 1Y | +145.0% | +120.1% | — |
| 3YCAGR | +103.9% | +82.5% | — |
| 5YCAGR | +53.3% | +40.0% | — |
| 10YCAGR | +23.8% | +9.9% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about Core Scientific, Inc. (CORZ) valuation, health, and returns.
Core Scientific, Inc. is estimated to be overvalued under our discounted cash flow framework. overvalued (implying -22.4% downside from DCF intrinsic value of $22.64)
Core Scientific, Inc. has multiple valuation anchors: DCF Intrinsic Value: $22.64 | Wall Street Analyst Target: $32.86 (implying +12.7% upside). A convergence of these signals offers higher conviction.
Core Scientific, Inc. displays weak financial health with a composite quality score of 25/100, supported by a Altman Z-Score of -2.2 (distress zone), Piotroski F-Score of 4/9.
Core Scientific, Inc. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
Core Scientific, Inc.'s current growth trajectory is Decelerating. The company achieved -37.5% 1Y revenue growth and +82.9% 1Y EPS growth, compared to its 3Y revenue CAGR of -20.7%.
Wall Street consensus is Buy based on 22 analysts, beating EPS expectations in 42% of recent quarters with a -3-quarter streak. The consensus price target represents a +12.7% change from current levels.
Investment risks for Core Scientific, Inc. include: -40.7% 1-year max drawdown, high beta (2.68x market volatility), elevated distress risk. Volatility risk is characterized by a beta of 2.68x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.